Top 10 Companies in the Asia Pacific Tranexamic Acid Market (2026): Market Leaders Powering Regional Healthcare

Tranexamic acid is a synthetic amino acid derivative commonly used as an antifibrinolytic agent, known for its ability to prevent or treat excessive bleeding. It works by inhibiting the activation of plasminogen to plasmin, a process that leads to fibrinolysis (the breakdown of blood clots). This medication is crucial in a variety of clinical settings, especially in surgery, trauma management, and gynecological treatments. With a growing range of applications, tranexamic acid has gained prominence in addressing bleeding disorders, including menorrhagia (heavy menstrual bleeding) and postpartum hemorrhage (excessive bleeding after childbirth).

Market Insight

The Asia Pacific tranexamic acid market is projected to grow from USD 156.3 million in 2025 to USD 204.8 million by 2034, registering a CAGR of 4.6% over the forecast period (2025–2034). The upward trajectory is largely driven by the rising volume of surgical procedures, heightened awareness of bleeding disorders, and a burgeoning demand for cosmetic applications such as skin‑whitening products. Japan, China, and India collectively command 75% of the regional share, with Japan accounting for 30%, China 25%, and India 20%.

Key statistics:

• Market Size in 2025: USD 156.3 million
• Projected Market Size in 2034: USD 204.8 million
• CAGR (2025–2034): 4.6%
• Major Markets: Japan (30%), China (25%), India (20%)

Asia Pacific Tranexamic Acid Market – View in Detailed Research Report

Top 10 Companies in the Asia Pacific Tranexamic Acid Market

10️⃣ 1. Daiichi Sankyo

Headquarters: Tokyo, Japan
Key Offering: Tranexamic Acid (USP25), Advanced surgical formulations

Daiichi Sankyo has long maintained a dominant presence in the Japanese market, leveraging its deep ties with national hospitals and surgical centers. The company’s focus on high‑purity USP25 grades supports complex procedures, reinforcing its reputation among surgeons who demand uncompromised efficacy.

Sustainability & Growth Initiatives:

• Investment in next‑generation delivery systems to reduce injection volume
• Partnerships with regional medical universities for clinical trials
• Commitment to reducing carbon footprint in manufacturing plants

9️⃣ 2. Emcure Pharmaceuticals

Headquarters: Hyderabad, India
Key Offering: Tranexamic Acid (BP2000), Cost‑effective generics

Emcure has capitalised on India’s expanding surgical base by offering competitively priced BP2000 formulations. The firm’s aggressive pricing strategy has pushed penetration into tier‑2 cities, where access to advanced bleeding control was previously limited.

Sustainability & Growth Initiatives:

• Expansion of regional manufacturing hubs to serve underserved areas
• Digital outreach programs targeting rural healthcare providers
• Investment in sustainable packaging solutions

8️⃣ 3. CSL Behring

Headquarters: Sydney, Australia
Key Offering: Tranexamic Acid (USP25), Global distribution network

CSL Behring’s global footprint allows it to supply tranexamic acid to a wide array of healthcare systems. Its robust logistics chain ensures timely delivery, a critical factor in emergency trauma care.

Sustainability & Growth Initiatives:

• Development of extended‑release formulations for chronic bleeding conditions
• Strategic alliances with local distributors in emerging markets
• Implementation of lean manufacturing processes to cut waste

7️⃣ 4. Pfizer Inc.

Headquarters: New York, USA
Key Offering: Tranexamic Acid (USP25), Broad therapeutic portfolio

Pfizer’s entry into the Asia Pacific market is underpinned by its strong R&D pipeline. The company’s focus on integrating tranexamic acid into multi‑modal treatment protocols has broadened its appeal beyond surgical settings.

Sustainability & Growth Initiatives:

• Collaboration with regional health ministries to subsidise cost for low‑income patients
• Investment in digital health platforms for patient education
• Commitment to achieving zero environmental impact in production by 2035

6️⃣ 5. Bayer AG

Headquarters: Leverkusen, Germany
Key Offering: Tranexamic Acid (USP25), Cosmetic applications

Bayer has diversified its portfolio to include cosmetic-grade tranexamic acid, tapping into the skin‑whitening market that is rapidly expanding across East Asia.

Sustainability & Growth Initiatives:

• Research into plant‑based excipients for greener formulations
• Partnerships with dermatology clinics to validate efficacy
• Targeted marketing campaigns in high‑growth markets such as South Korea and Thailand

5️⃣ 6. Fresenius Kabi

Headquarters: Bad Homburg, Germany
Key Offering: Tranexamic Acid (USP25), Advanced infusion systems

Fresenius Kabi’s focus on infusion technology aligns well with the need for rapid, controlled delivery of tranexamic acid during critical care scenarios.

Sustainability & Growth Initiatives:

• Development of single‑dose pre‑filled syringes to reduce waste
• Partnership with hospitals to implement real‑time monitoring of blood loss
• Adoption of renewable energy sources in production facilities

4️⃣ 7. Hikma Pharmaceuticals PLC

Headquarters: London, United Kingdom
Key Offering: Tranexamic Acid (BP2000), Global generics

Hikma’s global generics strategy positions it to capture market share in price‑sensitive segments while maintaining high quality standards.

Sustainability & Growth Initiatives:

• Expansion of low‑cost production lines in Asia
• Investment in community health programs to raise awareness of bleeding disorders
• Implementation of closed‑loop water recycling in manufacturing plants

3️⃣ 8. Sun Pharmaceutical Industries Ltd.

Headquarters: Mumbai, India
Key Offering: Tranexamic Acid (USP25), Cost‑effective generics

Sun Pharma’s extensive distribution network across India ensures that tranexamic acid reaches even remote healthcare facilities, supporting the country’s push for universal health coverage.

Sustainability & Growth Initiatives:

• Localized production to reduce import reliance
• Digital health outreach to educate practitioners on optimal dosing
• Adoption of ISO 14001 environmental management systems

2️⃣ 9. Jiangsu Hengrui Medicine Co., Ltd.

Headquarters: Nanjing, China
Key Offering: Tranexamic Acid (USP25), Innovative formulations

Jiangsu Hengrui has been a pioneer in developing extended‑release tranexamic acid, catering to chronic bleeding conditions and improving patient adherence.

Sustainability & Growth Initiatives:

• Investment in bioprocessing technologies to enhance yield
• Collaborations with academic institutions for clinical trials
• Commitment to reducing greenhouse gas emissions in manufacturing

1️⃣ 10. Sichuan Med‑Shine Pharmaceutical Co., Ltd.

Headquarters: Chengdu, China
Key Offering: Tranexamic Acid (BP2000), Market‑leading generics

Sichuan Med‑Shine’s aggressive marketing in Tier‑2 and Tier‑3 cities has positioned it as a household name for affordable tranexamic acid in China.

Sustainability & Growth Initiatives:

• Expansion of local manufacturing to meet rising demand
• Digital platforms for patient education and adherence tracking
• Implementation of waste‑reduction programs across production sites

Download FREE Sample Report

Get Full Report

Outlook

As the region continues to modernise its surgical and trauma care infrastructure, the demand for tranexamic acid is set to rise. The trend towards minimally invasive procedures, coupled with a shift towards outpatient care, will increase the need for rapid, reliable bleeding control. Concurrently, the cosmetic market’s appetite for skin‑whitening products offers a secondary growth channel that is less volatile than the clinical segment.

Future Trends

• Expansion of extended‑release formulations to reduce dosing frequency in chronic conditions.
• Integration of tranexamic acid into bundled care pathways for obstetric and gynecological services.
• Emergence of digital health tools that monitor bleeding risk and recommend prophylactic dosing.
• Growing regulatory emphasis on cost‑effectiveness and patient safety will drive adoption of high‑quality generics.
• Increased focus on sustainability in production, including renewable energy use and waste minimisation.

---

FAQ

What is the current market size of the Asia Pacific Tranexamic Acid market?

The market size is valued at USD 156.3 million in 2025, with projections to reach USD 204.8 million by 2034.

Which are the key companies operating in the Asia Pacific Tranexamic Acid market?

Key players include Daiichi Sankyo, Emcure Pharmaceuticals, CSL Behring, Pfizer Inc., Bayer AG, and Fresenius Kabi.

What are the key growth drivers in the Asia Pacific Tranexamic Acid market?

Growth drivers include increasing surgical procedures, rising awareness of bleeding disorders, and expanding healthcare access in rural areas.

Which regions dominate the Asia Pacific Tranexamic Acid market?

Japan, China, and India are the dominant regions, with Japan holding the largest market share.

What are the emerging trends in the Asia Pacific Tranexamic Acid market?

Emerging trends include growing demand for cosmetic applications, increased healthcare access in rural regions, and the development of extended‑release formulations.